Related Experiment Video
Updated: Sep 19, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Advancements in decoy oligodeoxynucleotides targeting STAT3 and STAT5 for cancer therapy
Maryam Mahjoubin-Tehran1, Samaneh Rezaei2, Ali H Eid3
1Department of Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
The Signal Transducer and Activator of Transcription (STAT) proteins are a group of cytoplasmic transcription factors. This group comprises seven members, named STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. These proteins are promising targets for anti-cancer treatment since cancer cells employ STAT activity to drive many of their processes more than normal cells do. Indeed, molecules targeting STATs, particularly STAT3 and STAT5, show great potential in cancer treatment, which explains the focus on developing STAT3 and 5 inhibitors. The less desirable pharmacological characteristics of peptidomimetics have shifted much of the attention to small molecules. However, current prospective molecules are not attractive enough for clinical studies, and further effort is rather necessary. Interestingly, oligonucleotide-based molecular methods, particularly decoy oligodeoxynucleotides (ODNs), show great potential in cancer treatment. Recent developments show that decoy ODNs and decoy peptides are two distinct forms of decoy techniques. Decoy ODNs can specifically bind to and inactivate certain transcription factors involved in disease development. In this review, we provide a concise appraisal of research dissecting the impact of decoy ODNs targeting STATs in cancer treatment.
Insights
Decoy oligodeoxynucleotides (ODNs) show promise for cancer treatment by targeting Signal Transducer and Activator of Transcription (STAT) proteins. This review explores the impact of decoy ODNs on STATs for anti-cancer therapies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Signal Transducer and Activator of Transcription (STAT) proteins are key cytoplasmic transcription factors involved in cancer cell proliferation.
- STAT3 and STAT5 are particularly crucial in cancer, making them prime targets for therapeutic intervention.
- Current small molecule inhibitors face limitations, necessitating exploration of alternative therapeutic strategies.
Purpose of the Study:
- To review the therapeutic potential of decoy oligodeoxynucleotides (ODNs) targeting STAT proteins in cancer treatment.
- To provide a concise appraisal of research on decoy ODNs and their impact on STATs in oncology.
- To highlight the advantages of decoy ODNs over traditional small molecules and peptidomimetics.
Main Methods:
- Literature review of studies investigating decoy ODNs targeting STAT proteins.
- Analysis of research on the specificity and efficacy of decoy ODNs in preclinical cancer models.
- Evaluation of the mechanisms by which decoy ODNs inactivate STAT transcription factors.
Main Results:
- Decoy ODNs demonstrate high specificity in binding and inactivating target STAT proteins.
- Oligonucleotide-based therapies, including decoy ODNs, present a promising alternative for cancer treatment.
- Decoy ODNs offer a distinct approach compared to decoy peptides for modulating transcription factor activity.
Conclusions:
- Decoy ODNs represent a viable and effective strategy for targeting STATs in cancer therapy.
- Further research and development of decoy ODNs are warranted to overcome current limitations in cancer treatment.
- The specificity and mechanism of action of decoy ODNs highlight their potential in targeted cancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:15Drugs that Stabilize Microtubules
01:20The JAK-STAT Signaling Pathway
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...